Suppr超能文献

人疱疹病毒 6 再激活的评估采用数字聚合酶链反应及其与异基因造血干细胞移植后 CD134 阳性 T 细胞动力学的关系。

Human Herpesvirus 6 Reactivation Evaluated by Digital Polymerase Chain Reaction and Its Association With Dynamics of CD134-Positive T Cells After Allogeneic Hematopoietic Stem Cell Transplantation.

机构信息

Division of Hematology, Department of Medicine, Tokyo, Japan.

Center for Transfusion Medicine and Cell Therapy, Keio University School of Medicine, Tokyo, Japan.

出版信息

J Infect Dis. 2019 Aug 9;220(6):1001-1007. doi: 10.1093/infdis/jiz237.

Abstract

BACKGROUND

Human herpesvirus 6 (HHV-6) causes life-threatening central nervous system disorders after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Recent studies implicated CD134 as a specific receptor of HHV-6B and demonstrated that its expression levels in CD4-positive T cells after allo-HSCT could be related to the reactivation of HHV-6. We prospectively evaluated the relationship between HHV-6 reactivation and CD134+ T cells in the recipients of allo-HSCT.

METHODS

HHV-6 viral load in plasma was quantitatively measured weekly after allo-HSCT by digital polymerase chain reaction in 34 patients. The ratio of CD134 in CD4+ T cells (CD134/CD4 ratio) was serially measured by flow cytometry before and after transplantation.

RESULTS

HHV-6 reactivation was detected in 23 patients (68%). The CD134/CD4 ratio before conditioning was significantly higher in patients with HHV-6 reactivation than in those without (median, 3.8% vs 1.5%, P < .01). In multivariate analysis, a higher CD134/CD4 ratio before conditioning was significantly associated with the incidence of HHV-6 reactivation (odds ratio, 10.5 [95% confidence interval, 1.3-85.1], P = .03).

CONCLUSIONS

A higher CD134/CD4 ratio before conditioning was associated with a higher risk of HHV-6 reactivation, suggesting that the rate may be a promising marker for predicting HHV-6 reactivation after allo-HSCT.

摘要

背景

人类疱疹病毒 6 型(HHV-6)可导致异基因造血干细胞移植(allo-HSCT)后危及生命的中枢神经系统疾病。最近的研究表明 CD134 是 HHV-6B 的特异性受体,并证明 allo-HSCT 后 CD4 阳性 T 细胞中 CD134 的表达水平可能与 HHV-6 的再激活有关。我们前瞻性评估了 allo-HSCT 受者中 HHV-6 再激活与 CD134+T 细胞之间的关系。

方法

通过数字聚合酶链反应在 34 例患者中每周定量测量 allo-HSCT 后血浆中的 HHV-6 病毒载量。在移植前后通过流式细胞术连续测量 CD4+T 细胞中 CD134 的比例(CD134/CD4 比值)。

结果

23 例患者(68%)检测到 HHV-6 再激活。与未发生 HHV-6 再激活的患者相比,发生 HHV-6 再激活的患者预处理前的 CD134/CD4 比值明显更高(中位数分别为 3.8%和 1.5%,P <.01)。在多变量分析中,预处理前较高的 CD134/CD4 比值与 HHV-6 再激活的发生率显著相关(优势比,10.5[95%置信区间,1.3-85.1],P =.03)。

结论

预处理前较高的 CD134/CD4 比值与 HHV-6 再激活的风险增加相关,表明该比率可能是预测 allo-HSCT 后 HHV-6 再激活的有前途的标志物。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验